Mucopolysaccharidosis Type III (Sanfilippo Syndrome)
A rare inherited disorder of heparan sulfate breakdown that primarily affects the brain, causing progressive developmental regression, behavioral changes, and neurodegeneration in young children. Specialist coordination is essential given the limited availability of disease-modifying therapy.
- Specialist Neurology Coordination
- Gene Therapy Trial Access
- Family Support Resources
- Estimated Incidence
- ~1 in 70,000 births (all subtypes combined)
- Inheritance Pattern
- Autosomal Recessive (4 subtypes: A, B, C, D)
- Typical Onset
- Early childhood (1–4 years)
- Therapy Access
- Gene therapy and CNS-targeted trials (investigational)
Condition Overview
Mucopolysaccharidosis type III (MPS III), known as Sanfilippo syndrome, is a rare inherited lysosomal storage disorder in which the body cannot properly break down heparan sulfate, a specific glycosaminoglycan. Unlike most other MPS types, the predominant impact of MPS III is on the central nervous system, with relatively mild physical and skeletal features.
MPS III has four genetically distinct subtypes (A, B, C, and D), each caused by deficiency of a different enzyme in the heparan sulfate degradation pathway. Despite different underlying genes, all subtypes share a similar clinical pattern: early developmental delay, followed by behavioral disturbance, progressive cognitive decline, and eventual loss of mobility and communication.
Because no enzyme replacement therapy currently crosses the blood-brain barrier effectively for MPS III, families benefit from early connection to specialist neurology care and emerging research, including gene therapy programs aimed specifically at the central nervous system.
Types and Subtypes
MPS III is divided into four subtypes based on which enzyme in the heparan sulfate degradation pathway is deficient. Clinical presentation is broadly similar across subtypes, though Type A is generally associated with the most rapid progression.
Symptoms and Signs
Children with Sanfilippo syndrome often appear to develop normally for the first 1 to 3 years before symptoms emerge, typically beginning with speech delay and behavioral changes rather than physical findings.
Causes and Risk Factors
MPS III is caused by mutations in one of four genes (SGSH, NAGLU, HGSNAT, or GNS), each encoding an enzyme required for breaking down heparan sulfate. Deficiency in any one of these enzymes causes heparan sulfate to accumulate, particularly within neurons.
Diagnosis and Investigations
Diagnosis often begins with developmental and behavioral concerns and is confirmed through biochemical and genetic testing.
Disease Phenotype and Severity Stratification
MPS III does not use a tumor-staging framework. Disease is generally described by clinical phase, reflecting the predominant pattern of developmental, behavioral, and neurological change over time.
Standard Treatment Options
There is currently no approved disease-modifying therapy that reliably crosses into the brain for MPS III, so management focuses on symptom control, behavioral support, and close monitoring for research trial opportunities.
Advanced & Emerging Therapies
Because conventional enzyme replacement therapy does not effectively cross the blood-brain barrier, research in MPS III is concentrated on CNS-directed approaches.
Gene Therapy
Subtype-specific gene therapy (AAV-based)
Several gene-addition programs targeting SGSH, NAGLU, or other relevant genes are in clinical trials, designed to deliver a working copy of the gene directly to the central nervous system.
Precision Medicine
Intrathecal or intracerebroventricular enzyme delivery
Investigational approaches deliver enzyme directly into the cerebrospinal fluid to bypass the blood-brain barrier.
Targeted
Substrate reduction approaches
Strategies aimed at reducing heparan sulfate production, rather than replacing the deficient enzyme, are being investigated in early-phase research.
Cellular Therapy
Hematopoietic stem cell transplant
Has shown limited and inconsistent benefit for the neurological manifestations of MPS III in published experience, and is not considered standard.
Biomarkers & Precision Diagnostics
Biochemical and genetic markers are essential both for diagnosis and for matching patients to subtype-specific research programs.
When a Second Opinion May Be Important
Given the limited treatment options and importance of subtype-specific research access, a specialist second opinion can meaningfully shape a family's path forward.
Clinical Trials and Research
Prognosis and Key Outcome Factors
MPS III is a progressive neurodegenerative condition, and without disease-modifying therapy, most children experience gradual decline in cognitive, motor, and communication abilities over time. Genetic subtype and rate of early progression both influence the disease trajectory.
Supportive Care and Living With MPS III
Because no broadly approved disease-modifying therapy currently exists, supportive and palliative-style care plays a central role in quality of life for children with Sanfilippo syndrome and their families.
How CancerFax Helps You Explore Treatment Options
CancerFax helps families affected by Sanfilippo syndrome access specialist review of medical reports, coordinate second opinions with metabolic and neurology specialists, and identify eligibility for subtype-specific gene therapy and CNS-directed clinical trials.
Get a free case reviewFrequently Asked Questions
MPS III, or Sanfilippo syndrome, is a rare inherited disorder in which the body cannot break down heparan sulfate, causing it to accumulate primarily in the brain and leading to progressive developmental regression.
The four subtypes are Type A (SGSH gene), Type B (NAGLU gene), Type C (HGSNAT gene), and Type D (GNS gene), each caused by deficiency of a different enzyme in the heparan sulfate breakdown pathway.
Early signs often include speech delay, hyperactivity, and sleep disturbance, typically appearing after a period of apparently normal development in the first few years of life.
Diagnosis combines urine heparan sulfate testing, enzyme activity assays for the relevant gene, and confirmatory genetic sequencing to identify the specific subtype.
There is currently no broadly approved disease-modifying therapy. Management focuses on symptom control and supportive care, while gene therapy and CNS-directed enzyme delivery are being studied in clinical trials.
Standard intravenous enzyme replacement therapy does not effectively cross the blood-brain barrier, which limits its usefulness for a disease that predominantly affects the central nervous system.
Several subtype-specific gene therapy programs are in active clinical trials, particularly for Type A and Type B, though these are investigational and not yet broadly approved.
Yes. All four subtypes follow an autosomal recessive inheritance pattern, requiring both parents to carry a mutated copy of the relevant gene.
Care typically involves metabolic genetics, pediatric neurology, behavioral therapy, speech and feeding therapy, and palliative care teams working together.
Yes. CancerFax can help coordinate medical report review, connect families with metabolic and neurology specialists for a second opinion, and identify eligibility for subtype-specific gene therapy and investigational CNS-directed clinical trials, including cross-border coordination where appropriate.
Get Specialist Guidance for Your Diagnosis
Connect with metabolic and genetic disease specialists, coordinate a second opinion, and explore therapy access options.